🌍 Society & Frontier risk-on · 1–3 years
A what‑if from the future

What if Radioligand-therapy boom lifts Novartis and isotope suppliers?

Radioligand therapies (Pluvicto-style) scale with isotope-supply investment, opening a high-growth oncology niche and lifting Novartis and isotope/radio-pharma names.

29%
our model probability
over 1–3 years
prediction markets — wisdom of the crowd
loading live odds…
Empirically anchored 29% · 90% range 1–57% · 18 analogues · measured class health 42% in 3 yr · 3% held back for the unknown
how we built this number — every step
Measured class rate — health ≈0.1843/yr → 42% in 3 yr42%
Analyst prior · editorial share 71% of the class30%
Pooled · weight 75%30%
Crowd — no liquid market
Reserve 3% · no extremizing (×1.0)30%
Published29%

The class rate is measured from our dated, sourced event library (decade-normalized Poisson — the full table is public at base_rates.json). The variant’s share within its class is the analyst’s editorial call, published so you can audit it. A wider range means thinner precedent. Full recipe: methodology · scored at Reality Check.

The butterfly cascade

How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.

Resolution timeline — how this probability is moving

Our model's odds (gold) over time vs the crowd's (Polymarket, blue), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. The gold path is an illustrative reconstruction anchored to today's estimate — real dated events, not a live re-estimate history.

loading the timeline…

What it would mean

If this plays out, it is a risk-on shock. Radioligand therapies (Pluvicto-style) scale with isotope-supply investment, opening a high-growth oncology niche and lifting Novartis and isotope/radio-pharma names. The trigger decomposes into signed root‑shocks — Biotech breakthrough ▲ · Industrial demand ▲ · Longevity ▲ · Risk appetite ▲ — which propagate through our causal graph to the markets below.

If it happens — the markets it would move

Biggest moves first. Projected moves are cascade-model priors; hist A–B% = what comparable past events actually did (measured abnormal returns), and model prior · unmeasured marks markets with no analogue backing yet. Tap any market for its price history.

MarketClassProjected move
1Solana SOLon Hyperliquid 📈 chartCrypto▲ +0.6%
hist -8.33–+4.23% · other way +4.67% (n=5)
2MicroStrategy MSTRon Hyperliquid 📈 chartEquity▲ +0.6%
hist -9.54–+18.66% · other way +0.34% (n=12)
3Hyperliquid (HYPE) HYPEon HyperliquidCrypto▲ +0.5%
model prior · unmeasured
4Nasdaq 100 NDXon Hyperliquid 📈 chartIndex▲ +0.5%
hist +0.15–+0.44% · other way +1.2% (n=12)
5Ether ETHon Hyperliquid 📈 chartCrypto▲ +0.5%
hist -0.9–+1.24% · other way -3.55% (n=6)
6Volatility (VIX) VIXon Hyperliquid 📈 chartVol▼ -0.3%
hist -1.05–+1.19% · other way +11.04% (n=12)
7S&P 500 SPXon Hyperliquid 📈 chartIndex▲ +0.3%
hist +0.06–+0.29% · other way -2.08% (n=12)
8Bitcoin BTCon Hyperliquid 📈 chartCrypto▲ +0.3%
hist -4.13–+7.6% · other way +1.13% (n=9)
9Tech sector XLK 📈 chartEquity▲ +0.3%
hist -0.26–+0.81% · other way +1.27% (n=12)
10Coinbase COINon Hyperliquid 📈 chartEquity▲ +0.2%
hist -8.08–+9.69% · other way -9.52% (n=3)
11Freeport (copper) FCX 📈 chartEquity▲ +0.2%
hist -2.06–+1.53% · other way -3.59% (n=12)
12Semiconductors SMHon Hyperliquid 📈 chartEquity▲ +0.2%
hist -0.46–+1.12% · other way +0.83% (n=12)

Probable recommendation

If the scenario above plays out, the probable cross‑asset positioning → a scenario‑conditional read, not personalized investment advice
For a common-man portfolio: A typical stock-heavy portfolio should benefit. Stay invested; you can lean modestly into the beneficiaries below.
Also moves (not yet on Hyperliquid): Tech sector +0.3% · Freeport (copper) +0.2%

Historical precedent — what analogous events actually did

Across 18 analogous events (overlap‑weighted), as abnormal returns — market beta stripped, so it's the event's own effect, not the market backdrop. Shown at 20 days (persistent) and 5 days (immediate); ↺ fades = the two horizons disagree. Confidence = consistency × sample × significance.

Wegovy 2021-06 First mRNA COVID-19 vaccine authorized 2020-12 Casgevy — first CRISPR gene-editing medicine approved 2023-12 mRNA pioneers win the Nobel 2023-10 First genetically-modified pig-to-human heart transplant 2022-01 AlphaFold cracks the protein-folding problem 2020-11 Human Genome Project completed 2003-04 Platinum hits an 11-year high on Chinese jewelry demand and deficit 2025-06 Palladium jumps after US pushes G7 sanctions on Russian metal 2024-10 Neuralink implants its first human brain-computer interface 2024-01 LK-99 room-temperature superconductor claim 2023-07 OpenAI releases GPT-4 2023-03 NIF achieves fusion ignition 2022-12 AlphaGo defeats Lee Sedol 2016-03 SpaceX lands an orbital rocket booster 2015-12 Silver hits 30-year high as JPMorgan and HSBC face manipulation suits 2010-10 Soviet August coup attempt against Gorbachev 1991-08 Volcker Saturday Night Special 1979-10
AssetHistory saysAbnormal (20d · 5d)HitnConfidencevs cascade
SOL SOLSHORT-8.4% · 5d -10.3%75%12 0.38⚠ differs
High-yield credit HYGSHORT-0.3% · 5d -0.2%68%15 0.23·
Bitcoin BTCLONG+7.5% · 5d -5.2% ↺ fades61%14 0.20✓ matches cascade
SPX SPXLONG+0.1% · 5d +0.7%60%18 0.18✓ matches cascade
MSTR MSTRLONG+18.2% · 5d -0.0% ↺ fades59%16 0.16✓ matches cascade
SMH SMHLONG+1.0% · 5d +1.0%61%16 0.16✓ matches cascade
10y yield DGS10LONG+10bp · 5d +3bp60%18 0.16·
US dollar DXYSHORT-0.3% · 5d -0.6%58%18 0.13·
Gold XAULONG+0.6% · 5d +0.1%54%16 0.06·
ETH ETHSHORT-1.3% · 5d -7.5%53%12 0.05⚠ differs
NDX NDXLONG+0.1% · 5d -0.4% ↺ fades53%17 0.04✓ matches cascade
Volatility VIXLONG+1.5% · 5d -3.6% ↺ fades44%17 0.00⚠ differs
XLK XLKLONG+0.6% · 5d +0.0%49%16 0.00✓ matches cascade
COIN COINLONG+10.2% · 5d +1.7%48%10 0.00✓ matches cascade

Methodology. Probability and impact are anchored to history and scored against what actually happens — wins and losses, in public, at Reality Check. Crowd odds live from Polymarket & Kalshi. By Vikas Singh, Quantitative Strategist. Updated 2026-07-03.